SOPHSOPHiA GENETICS SA
Is it safe?
Mostly sound, with a caveat: comfortable debt (AA), but big price swings.
Insiders were net sellers (-$669K, 90 days to Oct 8, 2026), selling is often routine.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -91% · now 17% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can SOPH take a bad year?
SOPHiA GENETICS SA holds $47M more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 73%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2025
- $47M
- Cash and short-term investments
- $95M
- Net cash
- $47M
- Operating profit, trailing twelve months
- −$68M
- Debt / equity
- 0.62×
- Annualised volatilitytwo years of daily moves
- 73%
- Worst drawdown on file
- −91%
- Below its 52-week high
- 17%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Health Information Services
Ranks #13 of 20 by RyuScore